Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers

Xenobiotica

Volumn 35, Issue 5, 2005, Pages 479-486

  Miura, M ^a   Kagaya, H ^a   Tada, H ^a   Sagae, Y ^a   Satoh, S ^b   Habuchi, T ^b   Suzuki, T ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2C19; Enantiomer; Lansoprazole; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RABEPRAZOLE; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOSELECTIVITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; STATISTICAL ANALYSIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KINETICS; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OMEPRAZOLE; STEREOISOMERISM; SUBSTRATE SPECIFICITY; TACROLIMUS;

EID: 22944484067     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500111562     Document Type: Article

References (18)

1. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. 2001. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clinical Pharmacokinetics 40:411-426.
2. Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y. 2002. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 73:303-304.
3. Ishizaki T, Horai Y. 1999. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Alimentary Pharmacology & Therapeutics 13:27-36.
4. Itoh K, Inoue K, Yanagiwara S, Kyoya H, Suzuki T. 1999. Rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Biological & Pharmaceutical Bulletin 22:7-9.
5. Kanazawa H, Okada A, Higaki M, Yokota H, Mashige F, Nakahara K. 2003. Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. Journal of Pharmaceutical and Biomedical Analysis 30:1817-1824.
6. Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG. 2002. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clinical Pharmacology and Therapeutics 72:90-99.
7. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing KF. 1995. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metabolism and Disposition 23:1315-1324.
8. Miura M, Tada H, Suzuki T. 2004a. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. Journal of Chromatography B 804:389-395.
9. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. 2004b. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. European Journal of Clinical Pharmacology 60:623-628.
10. Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. 2005. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. British Journal of Clinical Pharmacology. In press.
11. Nagaya H, Satoh H, Maki Y. 1990. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. Journal of Pharmacology and Experimental Therapeutics 252:1289-1295.
12. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K. 2001. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharmacological Research 18:721-727.
13. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, et al. 2000. Bioanalytical method validation-a revisit with a decade of progress. Pharmacological Research 17:1551-1557.
14. Swan SK, Hoyumpa AM, Merritt GJ. 1999. Review article: the pharmacokinetics of rabeprazole in health and disease. Alimentary Pharmacology & Therapeutics 13:11-17.
15. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Ishizaki T. 2001. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of 5-mephenytoin. Clinical Pharmacology and Therapeutics 69:108-113.
16. Tateno M, Nakamura N. 1991. Phase I study of lansoprazole (AG-1749) antiulcer agent: capsule form. Rinsho Iyaku 7:51-62 (Japanese).
17. Tybring G, Bottiger Y, Widen J, Bertilsson L. 1997. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clinical Pharmacology and Therapeutics 62:129-137.
18. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. 1995. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clinical Pharmacology and Therapeutics 58:143-154.